Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180924 | 1.00 | DYRK1A (0.38) | DYRK1AADORA2AMAPK1JAK2PDPK1 | |
| SCHEMBL6358084 | 0.75 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL14906033 | 0.71 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL30876173 | 0.71 | MAPK1 (0.35) | MAPK1KDM4ECCNB2CDK1CCNB1 | |
| SCHEMBL3950985 | 0.71 | PDPK1 (0.38) | DYRK1AMAPK1PDPK1CCNB2CDK1 | |
| SCHEMBL30316980 | 0.71 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL30988525 | 0.70 | MAPK1 (0.46) | DYRK1AMAPK1JAK2PDPK1CYP3A4 | |
| SCHEMBL12467739 | 0.69 | DYRK1A (0.37) | DYRK1AMAPK1PDPK1 | |
| SCHEMBL16946863 | 0.69 | DYRK1A (0.37) | DYRK1APDPK1GAA | |
| SCHEMBL1495296 | 0.68 | PDPK1 (0.48) | PDPK1KDM4ECYP3A4GAAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114837-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | Bayer Aktiengesellschaft (DE) | 2023-01-11 | — | — | EP | claimed |
| WO-2021176049-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-10 | — | — | WO | claimed |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4114837-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | Bayer Aktiengesellschaft (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021176049-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-10 | — | — | WO | disclosed |
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-16 | — | — | US | disclosed |
| WO-2018078009-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | disclosed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| WO-2014016434-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013063100-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013060029-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130096110-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2570415-A1 | N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | DYRK1A 521/4885ADORA2A 1519/4885MAPK1 148/4885 |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | DYRK1A 2953/4885ADORA2A 263/4885MAPK1 1463/4885 |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | DYRK1A 3719/4885ADORA2A 1730/4885MAPK1 3257/4885 |
| US-20130096110-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | DYRK1A 2953/4885ADORA2A 263/4885MAPK1 1463/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | DYRK1A 3719/4885ADORA2A 1730/4885MAPK1 3257/4885 |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | CDK12, CDK1, CDK15 | DYRK1A 473/4885ADORA2A 2829/4885MAPK1 465/4885 |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | DYRK1A 4272/4885ADORA2A 273/4885MAPK1 3296/4885 |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | DYRK1A 3719/4885ADORA2A 1730/4885MAPK1 3257/4885 |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | DYRK1A 521/4885ADORA2A 1519/4885MAPK1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.